HC Wainwright Brokers Reduce Earnings Estimates for ETON

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Stock analysts at HC Wainwright reduced their Q1 2025 earnings estimates for Eton Pharmaceuticals in a research report issued on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.09 for the quarter, down from their previous forecast of $0.12. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.14 EPS, FY2026 earnings at $0.85 EPS, FY2027 earnings at $1.13 EPS and FY2028 earnings at $1.28 EPS.

Separately, Craig Hallum upped their price target on Eton Pharmaceuticals from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, October 28th.

Eton Pharmaceuticals Stock Performance

Eton Pharmaceuticals stock opened at $10.46 on Friday. The stock’s 50 day moving average is $7.29 and its 200 day moving average is $4.93. Eton Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $11.11.

Insider Buying and Selling at Eton Pharmaceuticals

In other news, major shareholder Opaleye Management Inc. purchased 57,500 shares of the stock in a transaction dated Tuesday, September 10th. The shares were purchased at an average cost of $4.65 per share, with a total value of $267,375.00. Following the acquisition, the insider now directly owns 2,660,000 shares of the company’s stock, valued at $12,369,000. This represents a 2.21 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have acquired 85,600 shares of company stock worth $462,674. Insiders own 14.89% of the company’s stock.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. bought a new position in Eton Pharmaceuticals in the 3rd quarter worth $54,000. Westside Investment Management Inc. raised its holdings in Eton Pharmaceuticals by 2.0% in the 2nd quarter. Westside Investment Management Inc. now owns 585,400 shares of the company’s stock worth $1,926,000 after purchasing an additional 11,440 shares during the period. Acadian Asset Management LLC raised its holdings in Eton Pharmaceuticals by 13.7% in the 1st quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock worth $585,000 after purchasing an additional 18,898 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after purchasing an additional 30,167 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Eton Pharmaceuticals by 63.8% in the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after buying an additional 41,469 shares in the last quarter. 27.86% of the stock is owned by institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.